Antihypertensive therapy of bevacizumab-induced hypertension.

Antihypertensive therapy of bevacizumab-induced hypertension. - Antihypertensive therapy of bevacizumab-induced hypertension.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019287

Enrollment

Registered

2015-10-08

Start date

2015-10-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Pathologically confirmation of cancer. 2)Administration of bevacizumab (15mg/kg) is planned. 3)No prior therapy of anti-VEGF antibody drug. 4)No prior therapy of antihypertensive drug. 5)Written informed consent.

Exclusion criteria

Exclusion criteria: 1)Renal failure (Cre>=1.5mg/dL)

Design outcomes

Primary

Measure	Time frame
The primary endpoint is home blood pressure control ratio at three weeks after initiation of treatment with an antihypertensive agent.	—

Secondary

Measure	Time frame
The secondary endpoint is 1)Change of the home blood pressure due to treatment with antihypertensive agent for Bevacizumab-induced hypertension. 2)Change of the office blood pressure due to treatment with antihypertensive agent for Bevacizumab-induced hypertension. 3)adverse event due to treatment with antihypertensive agent for Bevacizumab-induced hypertension.	—

Countries

Japan

Contacts

Public ContactTakuya Oyakawa

Shizuoka Cancer Center Division of Cardiology

t.oyakawa@scchr.jp(+81)055-989-5222

Outcome results